Hospital Clínico San Carlos de Madrid -ko ikertzaileekin lankidetzan egindako argitalpenak (11)

2024

  1. ADAMTS13 recovery in acute thrombotic thrombocytopenic purpura after caplacizumab therapy

    Blood, Vol. 143, Núm. 18, pp. 1807-1815

2023

  1. Immune thrombotic thrombocytopenic purpura in older patients: Results from the Spanish TTP Registry (REPTT)

    British Journal of Haematology, Vol. 203, Núm. 5, pp. 860-871

  2. Recommendations for the Clinical Approach to Immune Thrombocytopenia: Spanish ITP Working Group (GEPTI)

    Journal of Clinical Medicine, Vol. 12, Núm. 20

2022

  1. Recommendations for the diagnosis and treatment of patients with thrombotic thrombocytopenic purpura

    Medicina Clinica, Vol. 158, Núm. 12, pp. 630.e1-630.e14

2021

  1. Incidence and clinical profile of venous thromboembolism in hospitalized COVID-19 patients from Madrid region

    Thrombosis research, Vol. 203, pp. 93-100

  2. Incidence, diagnosis, and outcome of immune-mediated thrombotic thrombocytopenic purpura: A nationwide survey by the Spanish registry of thrombotic thrombocytopenic purpura

    Journal of Clinical Apheresis, Vol. 36, Núm. 4, pp. 563-573

  3. Multicentric evaluation of the new HemosIL Acustar® chemiluminescence ADAMTS13 activity assay

    International Journal of Laboratory Hematology, Vol. 43, Núm. 3, pp. 485-493

2020

  1. Use of eltrombopag for patients 65 years old or older with immune thrombocytopenia

    European Journal of Haematology, Vol. 104, Núm. 3, pp. 259-270

2017

  1. Use of eltrombopag for secondary immune thrombocytopenia in clinical practice

    British Journal of Haematology, Vol. 178, Núm. 6, pp. 959-970

2015

  1. Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia

    American Journal of Hematology, Vol. 90, Núm. 3, pp. E40-E43

  2. Use of eltrombopag after romiplostim in primary immune thrombocytopenia

    British Journal of Haematology, Vol. 169, Núm. 1, pp. 111-116